Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EPPIC-Net EN21-01 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of 80 mg Daily of NRD135S.E1 Versus Placebo in Adult and Elderly Participants With Painful Diabetic Peripheral Neuropathy.

NCT05480228 is registered in ClinicalTrials.gov with James P. Rathmell, MD as lead sponsor.

NCT NCT05480228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05480228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EPPIC-Net EN21-01 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of 80 mg Daily of NRD135S.E1 Versus Placebo in Adult and Elderly Participants With Painful Diabetic Peripheral Neuropathy.
Lead sponsor
James P. Rathmell, MD
Phase
Phase 2
Overall status
Completed
Start date
September 21, 2022
Completion date
August 31, 2025
Enrollment
127 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

painful diabetic neuropathy